A retrospective study based on datas from marketscan commercial and supplemental medicare databases to evaluate the methodological challenges of comparative safety study of abatacept in rheumatoid arthritis patients : real world experience.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions

Most Recent Events

29 Jul 2015 New trial record
13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight